Skip main navigation

Military Health System

Clear Your Browser Cache

This website has recently undergone changes. Users finding unexpected concerns may care to clear their browser's cache to ensure a seamless experience.

Mid-Season Influenza Vaccine Effectiveness Against Laboratory-Confirmed Ambulatory Influenza: U.S. Active Component Service Members

Image of 48088663. This report provides an overview of the 2023-2024 mid-season analysis of influenza vaccine effectiveness against medically-attended ambulatory influenza infections.

This Surveillance Snapshot provides an overview of the 2023-2024 mid-season analysis of influenza VE against medically-attended ambulatory influenza infections among active component service members. Data from the Defense Medical Surveillance System, the NHRC’s respiratory surveillance program, and standardized laboratory data provided by the Defense Centers for Public Health–Portsmouth were used for this analysis.1,2 A case test-negative study design was implemented among the population of ACSMs from all services who were tested for influenza between December 1, 2023 and February 23, 2024—the period of peak influenza activity for the season. 

Cases were defined as individuals with a positive influenza result from a rapid antigen, reverse transcription polymerase chain reaction or culture influenza assay. Test-negative controls were individuals with a negative influenza result from a RT-PCR or culture influenza assay. Crude odds ratios were calculated and multivariate logistic regression was used to calculate adjusted ORs (adjusted for sex, age category, prior vaccination [any influenza vaccine in previous 5 years], and month of diagnosis) and 95% confidence intervals. VE estimates were defined as (1 - OR) x 100. 

Click on the table to access a 508-compliant PDF version

There were 3,540 cases—2,794 A (any subtype), 246 A(H3N2), 119 A(H1N1)pdm09, 751 B (any type)—and 16,411 TNCs. TNCs were more likely vaccinated (85.4%) than cases (82.5%). VE varied by influenza type (Table). Statistically significant VE was found against any influenza case with an adjusted VE of 21% (95% CI: 13, 29) and influenza A (any subtype) with an adjusted VE of 26% (95% CI: 18, 34). The VE point estimate against influenza A(H1N1)pdm09 and A(H3N2) showed effectiveness, but did not reach statistical significance (23% [95% CI: -23, 51] and 28% [95% CI: -1, 49], respectively). This mid-season assessment did not find the vaccine to be effective against influenza B ambulatory infections (-5% [95% CI: -30, 15]). 

The results of this analysis show low protection of the 2023-2024 seasonal influenza vaccines against medically-attended influenza A infections that resulted in ambulatory care visits among ACSMs. As these estimates were obtained during the middle of the influenza season, VE estimates and CIs may change when data from the full season are available and sample sizes increase. 

References

  1. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am J Public Health. 2002;92(12):1900-1904. doi:10.2105/ajph.92.12.1900 
  2. https://www.med.navy.mil/Naval-Medical-Research-Command/R-D-Commands/Naval-Health-Research-Center/Core-Research/Operational-Infectious Diseases/respiratory-surveillance-2023-2024

You also may be interested in...

Topic
Jun 6, 2024

Medical Surveillance Monthly Report

The Medical Surveillance Monthly Report, a peer-reviewed journal launched in 1995, is the Armed Forces Health Surveillance Division's flagship publication. The MSMR provides monthly evidence-based estimates of the incidence, distribution, impact, and trends of health-related conditions among service members.

Report
May 1, 2024

MSMR Vol. 31 No. 5 - May 2024

.PDF | 3.55 MB

The May 2024 MSMR features a report on mortality surveillance of active duty U.S. soldiers from 2014 to 2019; followed by three related reports on respiratory investigations, surveillance and forecasting, on: an outbreak of influenza and SARS-CoV-2 at the Armed Forces of the Philippines Health Service Education and Training Center, September–October ...

Article
May 1, 2024

Outbreak of Influenza and SARS-CoV-2 at the Armed Forces of the Philippines Health Service Education and Training Center, September 25–October 10, 2023

This report describes an investigation of a respiratory outbreak at the Armed Forces of the Philippines Health Service Education and Training Center by the Walter Reed Army Institute of Research-Armed Forces Research Institute of Medical Sciences and Armed Forces of the Philippines Collaborative Molecular Laboratory, demonstrating a common source ...

Article
Apr 1, 2024

Reportable Medical Events at Military Health System Facilities Through Week 9, Ending March 2, 2024

This report provides a monthly updatea of Reportable Medical Events documented in the Disease Reporting System internet (DRSi) by health care providers and public health officials throughout the Military Health System. Reportable Medical Events are a critical tool for monitoring, controlling, and preventing the occurrence and spread of diseases of ...

Report
Mar 1, 2024

MSMR Vol. 31 No. 3 - March 2024

.PDF | 1.34 MB

The March 2024 MSMR features a comparison of 2018 estimates from the HRBS and the PHA on tobacco and nicotine use among the U.S. military active component; followed by a report on coverage of HIV PrEP among active duty service members in 2023; supplemented by a Surveillance Snapshot of HIV PrEP prescriptions in 2023 in the active component; then a ...

Skip subpage navigation
Refine your search
Last Updated: May 07, 2024
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery